 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 908111
Online Users : 932
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/8646
|
| Title: | Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients |
| Authors: | Chang, TC;Shiah, HS;Yang, CH;Yeh, KH;Cheng, AL;Shen, BN;Wang, YW;Yeh, CG;Chiang, NJ;Chang, JY;Chen, LT |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Purpose: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. Methods: Patients were enrolled in cohorts of one to three to receive escalating dose of PEP02 in a phase I trial. PEP02, from 60 to 180 mg/m2, was given as a 90-min intravenous infusion, every 3 weeks. Results: A total of 11 patients were enrolled into three dose levels: 60 (one patient), 120 (six patients) and 180 mg/m2 (four patients). DLT was observed in three patients, one at 120 mg/m2 (grade 3 catheter-related infection) and two at 180 mg/m2 (grade 4 neutropenia lasting for >3 days in one, grade 4 hematological toxicities and grade 4 diarrhea in the other). MTD was determined as 120 mg/m2. Comparing with those after free-form irinotecan in the literature, the dose-normalized PK of SN-38 (the active metabolite) after PEP02 was characterized by lower C max, prolonged terminal half-life and higher AUC but with significant inter-individual variation. One patient who died of treatment-related toxicity had significantly higher C max and AUC levels of SN-38 than those of the other three patients at 180 mg/m2. Post hoc pharmacogenetic study showed that the patient had a combined heterozygosity genotype of UGT1A1∗6/∗28. Two patients had objective tumor response. Conclusions: PEP02 apparently modified the PK parameters of irinotecan and SN-38 by liposome encapsulation. The MTD of PEP02 monotherapy at 3-week interval is 120 mg/m2, which will be the recommended dose for future studies. |
| Date: | 2015-03 |
| Relation: | Cancer Chemotherapy and Pharmacology. 2015 Mar;75(3):579-586. |
| Link to: | http://dx.doi.org/10.1007/s00280-014-2671-x |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0344-5704&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000350350900016 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84923651982 |
| Appears in Collections: | [陳立宗] 期刊論文
[張俊彥] 期刊論文
[姜乃榕] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP84923651982.pdf | | 655Kb | Adobe PDF | 624 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
